S 525606

Drug Profile

S 525606

Alternative Names: cedar pollen allergy immunotherapy - Stallergenes/Shionogi; Cedar pollen sublingual immunotherapy; S-525606; STAGR 120

Latest Information Update: 26 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stallergenes SA
  • Developer Shionogi; Stallergenes Greer plc
  • Class Allergens; Antiallergics; Japanese cedar pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic rhinitis

Most Recent Events

  • 03 Aug 2015 Phase-II clinical trials in Allergic rhinitis in Japan (Sublingual)
  • 01 Oct 2014 Phase-I clinical trials in Allergic rhinitis in Japan (Sublingual)
  • 06 Sep 2010 Preclinical trials in Allergic rhinitis in Japan (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top